These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 15191378)

  • 1. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
    Lode H; Magyar P; Muir JF; Loos U; Kleutgens K;
    Clin Microbiol Infect; 2004 Jun; 10(6):512-20. PubMed ID: 15191378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia.
    Lode H; Aronkyto T; Chuchalin AG; Jaaskevi M; Kahnovskii I; Kleutgens K;
    Clin Microbiol Infect; 2004 May; 10(5):403-8. PubMed ID: 15113316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
    Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
    J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
    Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
    Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis.
    Solèr M; Lode H; Baldwin R; Levine JH; Schreurs AJ; van Noord JA; Maesen FP; Zehrer M;
    Eur J Clin Microbiol Infect Dis; 2003 Mar; 22(3):144-50. PubMed ID: 12649711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
    File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome.
    Hoepelman IM; Möllers MJ; van Schie MH; Greefhorst AP; Schlösser NJ; Sinninghe Damsté EJ; van de Moosdijk CN; Dalinghaus WH; Eland ME; Mol SJ; Rozenberg-Arska M
    Int J Antimicrob Agents; 1997 Jan; 9(3):141-6. PubMed ID: 9552709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and tolerability of pristinamycin vs amoxicillin-clavulanic acid combination in the treatment of acute community-acquired pneumonia in hospitalized adults].
    Poirier R; Chardon H; Beraud A; Debieuvre D; Petitprez P; Montestruc F; Lilienthal F; Janus C
    Rev Pneumol Clin; 1997; 53(6):325-31. PubMed ID: 9616826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections.
    Naber KG; Allin DM; Clarysse L; Haworth DA; James IG; Raini C; Schneider H; Wall A; Weitz P; Hopkins G; Ankel-Fuchs D
    Int J Antimicrob Agents; 2004 Jun; 23(6):596-605. PubMed ID: 15194131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
    Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
    Balgos AA; Rodriguez-Gomez G; Nasnas R; Mahasur AA; Margono BP; Tinoco-Favila JC; Sansores-Martinez RH; Hassan M; Beppo O; Wongsa A; Cukier A; Vargas F
    Int J Clin Pract; 1999; 53(5):325-30. PubMed ID: 10695094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I; Gogos CA; Bassaris H
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia.
    Speich R; Imhof E; Vogt M; Grossenbacher M; Zimmerli W
    Eur J Clin Microbiol Infect Dis; 1998 May; 17(5):313-7. PubMed ID: 9721959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.
    Léophonte P; File T; Feldman C
    Respir Med; 2004 Aug; 98(8):708-20. PubMed ID: 15303634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, randomized, investigator-blinded study of 5- and 10-day gatifloxacin versus 10-day amoxicillin/clavulanate in patients with acute bacterial sinusitis.
    Sher LD; McAdoo MA; Bettis RB; Turner MA; Li NF; Pierce PF
    Clin Ther; 2002 Feb; 24(2):269-81. PubMed ID: 11911557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections.
    Ferwerda A; Moll HA; Hop WC; Kouwenberg JM; Tjon Pian Gi CV; Robben SG; de Groot R
    J Antimicrob Chemother; 2001 Apr; 47(4):441-6. PubMed ID: 11266417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
    Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
    Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.